Company Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.
It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms.
This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices.
The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions.
It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries.
The company was founded in 1933 and is headquartered in Somerset, New Jersey.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 31, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17,800 |
| CEO | Alessandro Maselli |
Contact Details
Address: 14 Schoolhouse Road Somerset, New Jersey 08873 United States | |
| Phone | 732 537 6200 |
| Website | catalent.com |
Stock Details
| Ticker Symbol | CTLT |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001596783 |
| CUSIP Number | 148806102 |
| ISIN Number | US1488061029 |
| Employer ID | 20-8737688 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alessandro Maselli | President, Chief Executive Officer and Director |
| John J. Greisch M.B.A. | Executive Chairman of the Board |
| Matti M. Masanovich | Senior Vice President and Chief Financial Officer |
| Lisa Evoli | Senior Vice President and Chief Human Resources Officer |
| Ricky Hopson | President, Division Head for BioProduct Delivery and Chief of Staff |
| David McErlane | Group President of Biologics Segment |
| Michael J. Hatzfeld Jr. | Vice President and Chief Accounting Officer |
| Charles Lickfold | Senior Vice President and Chief Information Officer |
| Paul Surdez | Vice President of Investor Relations |
| Joseph A. Ferraro J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | POSASR | Filing |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 25-NSE | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |